A reduced dose of darunavir/ritonavir is effective in PI-experienced HIV-infected patients

Massimiliano Lanzafame, Stefano Bonora, Emanuela Lattuada, Andrea Calcagno, Sandro Vento

Research output: Contribution to journalLetter

2 Citations (Scopus)

Abstract

Darunavir (DRV) is an HIV-1 protease inhibitor that is used together with a low boosting dose of ritonavir as part of an antiretroviral therapy (ART) regimen in treatment-experienced and naïve HIVpositive patients. In naïve and experienced patients with no DRV-mutations, DRV is licensed at the dose of 800 mg plus 100 mg of ritonavir once daily. We report our results in seven ART-experienced HIV-infected patients, in whom a reduced dose of darunavir/ritonavir (600/100 mg once daily) successfully controlled viral replication.

Original languageEnglish
Pages (from-to)498-500
Number of pages3
JournalBrazilian Journal of Infectious Diseases
Volume15
Issue number5
DOIs
Publication statusPublished - Sep 1 2011

Keywords

  • HIV infections
  • Pharmacokinetics antiretroviral therapy, highly active

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'A reduced dose of darunavir/ritonavir is effective in PI-experienced HIV-infected patients'. Together they form a unique fingerprint.

  • Cite this